Table 3.

Follow up of 2 patients with transient BCA.

Months after infusion	Patient 1		Patient 2
	Absolute peripheral B cells/µL (% in WBC)	% CD19+ B cells in bone marrow	Absolute peripheral B cells/µL (% in WBC)	% CD19+ B cells in bone marrow
1-6	Absolute aplasia	0	Absolute aplasia	0
9	Absolute aplasia	0,49%	Absolute aplasia	0
10	Absolute aplasia	0,15%	Absolute aplasia
11	*6 (0,1)		*4 (0,3)
12	*2,3 (0,04)	**3,2%	*9 (0,7)	0,7%
13	0,1 (0,002)		*2 (0,1)
14			*6 (0,4)
15	Absolute aplasia		*5 (0,1)	**7,5%
18	0,5 (0,01)	0,12%	Absolute aplasia	**1,4%
24	Absolute aplasia		Absolute aplasia	0,75%
30	Absolute aplasia	0,02%
Follow-up	3 years Ongoing BCA and CR		2 years Ongoing BCA and CR

*Loss BCA EBMT criteria **Pennsylvania loss of BCA definition.